News
Soligenix's HyBryte (synthetic hypericin) offers a promising solution as a potential first-line therapy for early-stage CTCL. By addressing this critical gap in care, HyBryte has the potential to ...
Click here to view the custom infographic of the Soligenix Inc. editorial. Clickhere to view the custom infographic of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback